I joined AstraZenenca in April 2017 as an Early Phase Medical Oncologist. Previously I spent 12 years as a practising clinician at The University of Manchester and The Christie NHS Foundation Trust where I was medical lead for the Experimental Cancer Medicine Team.

My interest is in first-in-human, first-in-class and Phase 1 clinical trials of novel agents. As Director Physician in Early Phase Oncology, I lead the clinical development of a range of experimental therapies. I review clinical data from the Phase I/II trials and provide input on the strategic direction of the programme.

At AstraZeneca we have an exciting portfolio of pipeline drugs, particularly in the DNA Damage Response arena. This offers me a unique opportunity to contribute to scientifically driven combination trials and comparative studies to aid investment decisions.

My biggest motivation is giving patients the opportunity to access exciting new therapies to treat cancer. At AstraZeneca, I can do this by interacting with investigators across the world and have the privilege of working with an exceptional team of colleagues. Together, our drive and ambition allow me to make a difference on a scale much greater than that I could hope to achieve in academia.

At AstraZeneca there is a passion to drive forward through the science but with a patient-centric focus. This is important when planning a clinical trial and also when a study is recruiting, achieved by forging great relationships with investigators to ensure proactive and collaborative dialogue.

The training at AstraZeneca gives clinicians an unparalleled technical understanding of drug-development processes that is rarely available in clinical academia. AstraZeneca offers an environment in which physicians who are intelligent, inquisitive and with a passion to learn can thrive. As an integral part of my professional role, I am able to maintain my clinical practice through one clinical session per week as part of my professional charitable activities. 


At AstraZeneca I have the privilege of working with an exceptional team whose drive and ambition allow me to make a difference on a much greater scale.


The training at AstraZeneca gives clinicians a technical understanding of drug-development decisions and processes that is rarely available in clinical academia.


2016 National Researcher of the Year

The Christie Research and Education Awards

2014 Experimental Cancer Medicine Team

Leading cancer care, The Christie Staff Awards

2013 ESMO Award

Contribution to the ESMO Fellowship Programme

LATEST PROJECT

2012-2017 leading a 300% increase in trials activity at The Christie under my tenure.

2017 the first recipient of the Diploma in Experimental Therapeutics from the Faculty of Pharmaceutical Medicine

2016 Invited speaker at the European Society for Medical Oncology conference

2016 Successful application to Cancer Research UK to support an investigator-initiated commercial Phase Ib trial


Featured publications

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer

E Dean, D Jodrell, K Connolly, S Danson, J Jolivet, J Durkin, S Morris, ...

Journal of Clinical Oncology 27 (10), 1660-1666

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

E Dean, MR Middleton, T Pwint, H Swaisland, J Carmichael, ...

British Journal of Cancer 106 (3), 468

IAPs as a target for anticancer therapy

S Danson, E Dean, C Dive, M Ranson

Current Cancer Drug Targets 7 (8), 785-794

Biomarkers of apoptosis

TH Ward, J Cummings, E Dean, A Greystoke, JM Hou, A Backen, ...

British Journal of Cancer 99 (6), 841

Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic

EJ Dean, M Ranson, F Blackhall, SV Holt, C Dive

Cancer Treatment Rreviews 33 (2), 203-212

X-linked inhibitor of apoptosis protein as a therapeutic target

EJ Dean, M Ranson, F Blackhall, C Dive

Expert Opinion on Therapeutic Targets 11 (11), 1459-1471

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors

F Andre, M Ranson, E Dean, A Varga, R Van der Noll, PK Stockman, ...

Cancer Research 73 (8 Supplement), LB-145-LB-145

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC

EJ Dean, T Ward, C Pinilla, R Houghten, K Welsh, G Makin, M Ranson, ...

British Journal of Cancer 102 (1), 97

First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014

B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ...

Clinical Cancer Research 21 (15), 3412-3419

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study

M Ranson, M Reck, A Anthoney, AR Hanauske, E Dean, I Melezinek, ...

Annals of Oncology 21 (11), 2233-2239

Advances in the management of melanoma: targeted therapy, immunotherapy and future directions

E Dean, P Lorigan

Expert Review of Anticancer Therapy 12 (11), 1437-1448

First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors

U Banerji, EJ Dean, M Gonzalez, AP Greystoke, B Basu, M Krebs, ...

Journal of Clinical Oncology 30 (15_suppl), 3004-3004

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors

U Banerji, M Ranson, JHM Schellens, T Esaki, E Dean, A Zivi, ...

Cancer Research 73 (8 Supplement), LB-66-LB-66

Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer

EJ Dean, J Cummings, A Roulston, M Berger, M Ranson, F Blackhall, ...

Neoplasia 13 (4), 339-347

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin

M Ranson, H Shaw, J Wolf, M Hamilton, S McCarthy, E Dean, A Reid, ...

Cancer Chemotherapy and Pharmacology 66 (1), 53-58

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

A Greystoke, E Dean, MP Saunders, J Cummings, A Hughes, M Ranson, ...

British Journal of Cancer 107 (9), 1518

Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker

MH Olofsson, J Cummings, W Fayad, S Brnjic, R Herrmann, M Berndtsson, ...

Cancer Biomarkers 5 (3), 117-125

Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients

R Stovold, SL Meredith, JL Bryant, M Babur, KJ Williams, EJ Dean, C Dive, ...

British Journal of Cancer 108 (8), 1704

A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non–small-cell lung cancer

E Felip, M Ranson, S Cedrés, E Dean, M Brewster, P Martínez, V McNally, ...

Clinical Lung Cancer 13 (6), 432-441

A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours

J Jolivet, E Dean, TH Ward, O Denneny, C Jacob, P Goodege, C Dive, ...

Journal of Clinical Oncology 26 (15_suppl), 3541-3541

Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors

C Rolfo, H Swaisland, K Leunen, A Rutten, P Soetekouw, S Slater, ...

Advances in Therapy 32 (6), 510-522

Biomarkers of cell death applicable to early clinical trials

E Dean, A Greystoke, M Ranson, C Dive

Experimental Cell Research 318 (11), 1252-1259

An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib

J Mateo, V Moreno, A Gupta, SB Kaye, E Dean, MR Middleton, ...

Targeted Oncology 11 (3), 401-415

Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

DM Hyman, L Smyth, PL Bedard, A Oza, E Dean, A Armstrong, J Lima, ...

Molecular Cancer Therapeutics 14 (12 Supplement 2), B109-B109

A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors

LR Molife, EJ Dean, M Blanco-Codesido, MG Krebs, AT Brunetto, ...

Clinical Cancer Research 20 (24), 6284-6294

Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors

G Daniele, M Ranson, M Blanco-Codesido, EJ Dean, KJ Shah, M Krebs, ...

Journal of Clinical Oncology 30 (15_suppl), 3030-3030

Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase

A Gupta, V Moreno, EJ Dean, Y Drew, S Nicum, M Ranson, R Plummer, ...

Journal of Clinical Oncology 30 (15_suppl), 3051-3051

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers

U Banerji, EJ Dean, JA Perez-Fidalgo, G Batist, PL Bedard, B You, ...

Journal of Clinical Oncology 33 (15_suppl), 2500-2500

Targeted therapies in epithelial ovarian cancer

E Dean, L El-Helw, J Hasan

Cancers 2 (1), 88-113

Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640

EJ Dean, GS Falchook, MR Patel, AJ Brenner, JR Infante, HT Arkenau, ...

Journal of Clinical Oncology 34 (15_suppl), 2512-2512

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

JC Soria, HK Gan, SP Blagden, R Plummer, HT Arkenau, M Ranson, ...

Annals of Oncology 27 (12), 2268-2274

A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients

E Felip, M Ranson, S Cedres, E Dean, E De Droogh, M Brewster, ...

Journal of Clinical Oncology 26 (15_suppl), 19134-19134

Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792)

ER Plummer, EJ Dean, TRJ Evans, A Greystoke, K Herbschleb, ...

Journal of Clinical Oncology 34 (15_suppl), 2513-2513

SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting

E Dean, N Steele, HT Arkenau, F Blackhall, NM Haris, C Lindsay, S Rafii, ...

Annals of Oncology 27 (suppl_6)

Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors

IH Zubairi, EJ Dean, LR Molife, JS Lopez, M Ranson, F El-Khouly, ...

Journal of Clinical Oncology 34 (15_suppl), 2524-2524

AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

DM Hyman, L Smyth, PL Bedard, A Oza, E Dean, A Armstrong, J Lima, ...

Molecular Cancer Therapeutics 14

Results of OAK: A phase 1, open-label, multicentre study to compare two dosage forms of AZD5363 and to explore the effect of food on the pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in patients with advanced solid malignancies

EJ Dean, U Banerji, JHM Schellens, M Krebs, B Jimenez, R van der Noll, ...

Journal of Clinical Oncology 33 (15_suppl), 2577-2577

Evidence of activity of a new mechanism of action (MoA): a first-in-human study of the first-in-class fatty acid synthases (FASN) inhibitor, TVB-2640, as monotherapy or in combinations

HT Arkenau, M Voskoboynik, J Infante, A Brenner, M Patel, E Borazanci, ...

Proceedings of the European Cancer Congress 2015, 25-29

AKT Inhibition in Solid Tumors With AKT1 Mutations

DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...

Journal of Clinical Oncology, JCO. 2017.73. 0143

Abstract CT147: phase I studies of AZD1208, a PIM kinase inhibitor, in patients with recurrent or refractory acute myelogenous leukemia or advanced solid tumors

J Cortes, K Tamura, DJ DeAngelo, J de Bono, D Lorente, M Minden, ...

Cancer Research 76 (14 Supplement), CT147-CT147

Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole, or letrozole: Phase I study

R Plummer, HMW Verheul, MHG Langenberg, K Leunen, LR Molife, ...

Journal of Clinical Oncology 34 (15_suppl), 2562-2562

A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma

EJ Dean, U Banerji, R Girotti, I Niculescu-Duvaz, F Lopes, L Davies, ...

Journal of Clinical Oncology 34 (15)

Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours

M Ranson, E Dean, T Ward, J Cummings, L Robson, J Durkin, J Jolivet, ...

Molecular Cancer Therapeutics 6 (11 Supplement), C163-C163